Federal Marijuana Prohibition: History, Current Status, and Reform Efforts

Executive Summary

Federal marijuana prohibition, rooted in the Controlled Substances Act of 1970, classifies cannabis as a Schedule I narcotic alongside heroin—a designation that has shaped five decades of enforcement, blocked medical research, and created a $30 billion state-legal industry operating in defiance of federal law. Despite 38 states legalizing medical cannabis and 24 permitting adult-use sales as of May 2026, marijuana remains illegal under 21 U.S.C. § 812, exposing state-licensed operators to federal prosecution, IRS penalties under 26 U.S.C. § 280E, and banking restrictions. The Drug Enforcement Administration initiated a rescheduling process in 2024 following a Department of Health and Human Services recommendation to move cannabis to Schedule III, a shift that would preserve prohibition while easing research barriers and tax burdens. Advocacy coalitions including the Cannabis Unity Coalition intensified lobbying efforts in 2026, pressing Congress for descheduling legislation that would remove marijuana from the Controlled Substances Act entirely. The conflict between state legalization and federal prohibition has created operational chaos for multi-state operators, locked patients out of federal housing and employment, and generated an estimated $15 billion in excess tax revenue since 2014 through 280E enforcement alone.

Why Federal Prohibition Matters

Federal marijuana prohibition affects 128 million Americans living in adult-use states, 4,800 state-licensed cannabis businesses, and an estimated 6 million registered medical patients who face federal prosecution risk despite state compliance. The Schedule I classification under the Controlled Substances Act carries consequences extending far beyond criminal penalties. State-licensed cannabis operators cannot deduct ordinary business expenses under 26 U.S.C. § 280E, resulting in effective tax rates exceeding 70 percent and forcing profitable companies into quarterly losses. Banks operating under federal charters refuse accounts to cannabis businesses, driving the industry toward cash operations that invite theft and complicate tax compliance. Federal prohibition blocks interstate commerce, forcing each state to build redundant cultivation, processing, and distribution infrastructure while prohibiting the efficient wholesale markets that characterize legal agricultural commodities. Medical researchers face DEA licensing requirements and can only study cannabis grown at a single federally contracted facility at the University of Mississippi, restricting clinical trials that could establish FDA-approved medications. Veterans receiving care through the Department of Veterans Affairs cannot receive medical cannabis recommendations from VA physicians, even in states where medical programs operate legally. Public housing tenants face eviction for state-legal cannabis use under federal property rules. Federal employees in legalized states risk termination for off-duty consumption that would be lawful under state law. The economic scale is substantial. The state-legal cannabis industry generated $28.3 billion in sales during 2025 according to industry analytics firm BDSA, supporting approximately 428,000 full-time equivalent jobs. Federal prohibition prevents these businesses from accessing capital markets, listing on major stock exchanges, or securing standard business loans, forcing reliance on private equity at punitive rates and stifling growth. Multi-state operators structured as holding companies navigate complex legal architectures to avoid direct plant-touching activities at the parent level, adding compliance costs that smaller operators cannot absorb.

The Origins and Evolution of Federal Cannabis Prohibition

Federal marijuana prohibition emerged from early 20th-century moral panic, racial animus, and bureaucratic expansion, culminating in the 1970 Controlled Substances Act that established the current Schedule I classification without scientific review.

Early Federal Regulation: 1906-1937

Cannabis appeared in the United States Pharmacopeia from 1850 through 1942 as a recognized medicine. The Pure Food and Drug Act of 1906 required labeling of cannabis content but did not prohibit sales. State-level prohibition began in the 1910s, with Massachusetts enacting the first state ban in 1911. By 1931, 29 states had restricted cannabis, often through laws targeting "locoweed" or "Mexican marijuana" with explicitly xenophobic legislative records. The Federal Bureau of Narcotics, established in 1930 under Commissioner Harry Anslinger, launched a public campaign linking marijuana to violence and moral degradation. Anslinger testified before Congress in 1937 that "Marihuana is an addictive drug which produces in its users insanity, criminality, and death." The Marihuana Tax Act of 1937 imposed registration and transfer taxes that functionally prohibited cannabis without formally criminalizing possession, surviving constitutional challenge in United States v. Sanchez (1950).

The Controlled Substances Act: 1970

Congress passed the Comprehensive Drug Abuse Prevention and Control Act of 1970, including Title II—the Controlled Substances Act—as part of President Richard Nixon's law enforcement agenda. The Act established five schedules based on abuse potential, accepted medical use, and safety. Schedule I, the most restrictive category, requires findings that a substance has high abuse potential, no currently accepted medical use in treatment in the United States, and lacks accepted safety for use under medical supervision. Congress placed marijuana in Schedule I temporarily pending review by the Shafer Commission, formally the National Commission on Marihuana and Drug Abuse. The Commission's 1972 report recommended decriminalization of possession for personal use, concluding that "neither the marihuana user nor the drug itself can be said to constitute a danger to public safety." President Nixon rejected the findings. Marijuana remained in Schedule I under 21 U.S.C. § 812(c), Schedule I(c)(10).

Petition Challenges and Judicial Review: 1972-2013

The National Organization for the Reform of Marijuana Laws filed a rescheduling petition with the DEA in 1972. After 16 years of administrative proceedings, DEA Administrative Law Judge Francis Young ruled in 1988 that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man" and recommended rescheduling to Schedule II. DEA Administrator John Lawn rejected the recommendation in 1989, a decision upheld by the D.C. Circuit Court of Appeals in Alliance for Cannabis Therapeutics v. DEA (1994). Subsequent rescheduling petitions filed in 1995, 2002, and 2011 followed similar trajectories: years of administrative delay, requests for scientific review from the Department of Health and Human Services, and ultimate denial. The 2011 petition filed by governors of Washington and Rhode Island was denied in 2016, with the DEA concluding that cannabis lacked accepted medical use under the five-part test established in Alliance for Cannabis Therapeutics.

State Legalization and Federal Enforcement Policy: 1996-2024

California voters approved Proposition 215 in 1996, establishing the first state medical cannabis program and creating direct conflict with federal law. The Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative (2001) that medical necessity is not a defense to Controlled Substances Act violations, and in Gonzales v. Raich (2005) that Congress may criminalize intrastate cultivation and possession under the Commerce Clause even when state law permits it. The Obama administration issued the Ogden Memorandum in 2009 and the Cole Memorandum in 2013, directing federal prosecutors to deprioritize enforcement against state-compliant cannabis operations that did not implicate federal priorities such as distribution to minors or diversion to prohibition states. The Trump administration rescinded the Cole Memorandum in January 2018 through the Sessions Memorandum, restoring prosecutorial discretion, though few federal cases against state-licensed operators materialized. Congress enacted incremental reforms through appropriations riders. The Rohrabacher-Farr Amendment, first passed in 2014 and renewed annually, prohibits the Department of Justice from using funds to prevent states from implementing medical cannabis laws. The 2018 Agriculture Improvement Act removed hemp—defined as cannabis containing less than 0.3 percent delta-9 tetrahydrocannabinol—from Schedule I, legalizing hemp cultivation and creating a regulatory gap for intoxicating hemp-derived cannabinoids.

The Rescheduling Process: 2022-Present

President Joe Biden directed the Secretary of Health and Human Services and the Attorney General to review marijuana's scheduling in October 2022. The Department of Health and Human Services completed a scientific review in August 2023, recommending rescheduling to Schedule III based on findings that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking in May 2024, initiating the formal rescheduling process under the Administrative Procedure Act. The proposed rule would maintain federal prohibition while reclassifying cannabis alongside anabolic steroids and ketamine in Schedule III. State-licensed operators would gain access to standard business tax deductions under 26 U.S.C. § 162, eliminating 280E penalties, but interstate commerce would remain prohibited and criminal penalties for unlicensed activity would persist. The DEA scheduled administrative hearings for late 2024, with a final rule anticipated in 2025 or 2026 pending resolution of public comments and testimony from stakeholders including the cannabis industry, law enforcement, and medical organizations.

Key Players in the Federal Prohibition Debate

Federal marijuana policy involves executive agencies with conflicting mandates, congressional factions divided along partisan and generational lines, industry coalitions seeking regulatory clarity, and advocacy organizations pursuing full descheduling.

Drug Enforcement Administration

The DEA holds statutory authority to schedule controlled substances under 21 U.S.C. § 811, subject to scientific review by the Department of Health and Human Services. The agency operates as the primary federal enforcement body for Controlled Substances Act violations, managing registrations for researchers and manufacturers. DEA leadership historically opposed rescheduling, with former Administrator Anne Milgram stating in 2023 congressional testimony that the agency would follow the science-based review process. The DEA's proposed Schedule III rule represents the first time the agency has supported moving cannabis to a less restrictive schedule.

Department of Health and Human Services and Food and Drug Administration

HHS conducts the scientific and medical evaluation required for scheduling decisions under 21 U.S.C. § 811(b). The FDA, operating within HHS, evaluates whether substances have accepted medical use through an eight-factor analysis examining chemistry, pharmacology, toxicology, and therapeutic applications. The FDA approved Epidiolex, a CBD-based medication for epilepsy, in 2018, and synthetic THC medications including dronabinol (Marinol) in 1985. The HHS recommendation to reschedule cannabis to Schedule III marked a significant policy shift, with HHS Assistant Secretary for Health Rachel Levine signing the recommendation in August 2023.

Congressional Leadership and Caucuses

The Congressional Cannabis Caucus, co-chaired by Representatives Earl Blumenauer and Barbara Lee, has advocated for federal reform since 2017. Senate Majority Leader Chuck Schumer introduced the Cannabis Administration and Opportunity Act in 2022, proposing descheduling and federal taxation, though the bill did not advance to a floor vote. Republican support for reform has grown among libertarian-leaning members, with Representatives Nancy Mace and Dave Joyce introducing the States Reform Act in 2021 to remove cannabis from the Controlled Substances Act while establishing federal regulatory oversight. Appropriations committees have used spending bills to constrain enforcement, renewing the Rohrabacher-Farr Amendment annually and adding provisions protecting state hemp programs. The House passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act in 2020 and 2022, descheduling cannabis and expunging federal convictions, but the legislation stalled in the Senate both times.

Cannabis Unity Coalition and Industry Groups

The Cannabis Unity Coalition, formed in 2025, represents multi-state operators, ancillary businesses, and advocacy organizations lobbying for comprehensive federal reform. The coalition's May 2026 lobbying effort in Washington, D.C., focused on descheduling rather than rescheduling, arguing that Schedule III classification would preserve criminal penalties and interstate commerce barriers while providing insufficient relief for social equity operators unable to afford compliance costs. The National Cannabis Industry Association and the U.S. Cannabis Council represent licensed operators seeking regulatory clarity, banking access, and tax reform. These groups supported the SAFE Banking Act, which passed the House seven times between 2019 and 2024 but failed to advance in the Senate. Industry coalitions have split on rescheduling, with larger MSOs viewing Schedule III as an acceptable incremental step and smaller operators and social equity advocates demanding full descheduling.

Opposition and Law Enforcement Groups

Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, opposes legalization and rescheduling, citing public health concerns about youth access and impaired driving. The organization argues that commercialization has increased high-potency THC products and cannabis use disorder diagnoses. Law enforcement organizations including the National Sheriffs' Association have historically opposed legalization, though some state-level police chiefs in legalized states have supported reform to reduce enforcement burdens.

Legal and Regulatory Framework

Federal marijuana prohibition rests on the Controlled Substances Act's scheduling system, Commerce Clause authority, and a complex web of statutes governing taxation, banking, employment, and immigration that create operational barriers for state-legal cannabis businesses.

Controlled Substances Act Scheduling

The Controlled Substances Act establishes five schedules at 21 U.S.C. § 812. Schedule I requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Marijuana appears in Schedule I(c)(10) alongside heroin, LSD, and peyote. Penalties for manufacturing, distributing, or possessing with intent to distribute marijuana range from five years to life imprisonment depending on quantity under 21 U.S.C. § 841, with mandatory minimum sentences for quantities exceeding 100 kilograms. The Attorney General may reschedule substances through rulemaking under 21 U.S.C. § 811(a), following an eight-factor analysis by the Secretary of Health and Human Services evaluating scientific evidence, abuse potential, and medical utility. The Administrative Procedure Act governs the rescheduling process, requiring notice, public comment, and administrative hearings if requested by interested parties.

Tax Code Section 280E

Section 280E of the Internal Revenue Code, codified at 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. The provision was enacted in 1982 following a Tax Court decision allowing a cocaine trafficker to deduct business expenses. The IRS applies 280E to state-licensed cannabis operators, disallowing deductions for rent, salaries, marketing, and other costs while permitting only cost of goods sold deductions under Treas. Reg. § 1.471-3. The effective tax rate for cannabis businesses under 280E ranges from 70 to 90 percent of gross profit according to industry analyses. Rescheduling to Schedule III would eliminate 280E penalties, as the statute applies only to Schedule I and II substances. The Congressional Research Service estimated in 2024 that rescheduling would reduce federal tax revenue by $5 billion to $8 billion over ten years.

Banking and Financial Services

The Bank Secrecy Act, 31 U.S.C. § 5318(g), requires financial institutions to file Suspicious Activity Reports for transactions involving illegal activity. Federal banking regulators have interpreted this to require SAR filings for cannabis-related accounts, creating compliance burdens that deter banks from serving the industry. The Financial Crimes Enforcement Network issued guidance in 2014 establishing "marijuana-limited" SAR categories for state-compliant businesses, but most federally insured banks declined to offer services. The SAFE Banking Act, passed by the House in seven separate sessions between 2019 and 2024, would prohibit federal banking regulators from penalizing institutions that serve state-licensed cannabis businesses. The legislation has not advanced in the Senate, where concerns about enabling an illegal industry and lack of comprehensive reform provisions have blocked floor votes. As of 2026, fewer than 800 of approximately 4,500 federally insured banks and credit unions serve cannabis clients according to FinCEN data.

Employment and Federal Benefits

Federal employees are subject to drug-free workplace policies under 41 U.S.C. § 8103, prohibiting marijuana use regardless of state law. The Department of Transportation requires drug testing for safety-sensitive positions under 49 C.F.R. Part 40, disqualifying drivers, pilots, and rail workers who test positive for THC. Veterans receiving care through the Department of Veterans Affairs cannot receive medical cannabis recommendations from VA physicians under 38 U.S.C. § 7402, though the VA will not deny benefits based on participation in state programs. Public housing tenants face eviction for marijuana use under the Quality Housing and Work Responsibility Act of 1998, 42 U.S.C. § 1437d(l)(6), which requires lease provisions for termination based on drug-related criminal activity. Immigration law treats marijuana offenses as grounds for inadmissibility and deportation under 8 U.S.C. § 1182(a)(2)(A)(i)(II), with no exception for state-legal activity.

State-by-State Legal Status

As of May 2026, 38 states and four territories have legalized medical cannabis, 24 states and two territories permit adult-use sales, and federal prohibition creates a patchwork of conflicting state regulations that prevent interstate commerce and uniform standards.

State	Medical Legal	Adult-Use Legal	Possession Limit (Adult-Use)	Home Cultivation
California	1996	2016	1 oz flower, 8g concentrate	6 plants
Colorado	2000	2012	1 oz flower, 8g concentrate	6 plants (3 mature)
New York	2014	2021	3 oz flower, 24g concentrate	6 plants (3 mature)
Florida	2016	No	N/A	No
Texas	2015 (low-THC only)	No	N/A	No
Illinois	2013	2020	30g flower, 5g concentrate	No (medical only)
Massachusetts	2012	2016	1 oz flower, 5g concentrate	6 plants (12 per household)
Ohio	2016	2023	2.5 oz flower	6 plants (12 per household)

Medical-Only States

Florida operates the largest medical-only program with approximately 800,000 registered patients as of 2026. The state's constitutional amendment limits medical cannabis to patients with qualifying conditions certified by licensed physicians, with no home cultivation permitted. A 2024 ballot initiative to legalize adult-use sales failed with 57 percent support, short of the 60 percent threshold required for constitutional amendments in Florida. Texas maintains a restrictive low-THC medical program limited to patients with epilepsy, terminal cancer, and PTSD, with products capped at 1 percent THC. The Texas Compassionate Use Program served approximately 50,000 patients as of 2025. Legislative efforts to expand qualifying conditions and increase THC limits have advanced incrementally, with the 2023 legislature raising the THC cap from 0.5 percent to 1 percent.

Adult-Use States

Colorado and Washington launched the first regulated adult-use markets in 2014 following voter approval in 2012. Colorado's market generated $1.6 billion in sales during 2025, contributing $423 million in tax revenue. The state allows home cultivation of six plants per adult, with a 12-plant maximum per residence. New York legalized adult-use cannabis in 2021 but delayed retail sales until December 2022 due to regulatory development and licensing litigation. The state prioritized social equity applicants for initial licenses, reserving the first 150 retail licenses for individuals with prior cannabis convictions or from communities disproportionately impacted by enforcement. New York's market reached $1.2 billion in sales during 2025 despite competition from unlicensed storefronts that proliferated during the regulatory delay. Ohio voters approved adult-use legalization through a ballot initiative in November 2023, with sales commencing in August 2024. The state allows possession of 2.5 ounces and home cultivation of six plants per adult, with a 12-plant household maximum. Ohio's medical program transitioned existing dispensaries to dual-license operations, creating immediate retail access.

Prohibition States

Twelve states maintain full prohibition of cannabis for any purpose as of May 2026: Idaho, Wyoming, Kansas, Nebraska, South Dakota, Wisconsin, Indiana, Kentucky, Tennessee, South Carolina, Georgia, and Iowa. These states enforce criminal penalties for possession, with Idaho and Kansas treating any possession as a misdemeanor punishable by up to one year in jail and $1,000 fines. South Dakota voters approved medical and adult-use legalization in 2020, but the state Supreme Court invalidated the adult-use measure on procedural grounds in 2021. A subsequent adult-use initiative failed in 2022. The state's medical program operates under restrictive regulations with approximately 15,000 registered patients.

Market and Business Implications

Federal prohibition forces state-legal cannabis operators to navigate effective tax rates exceeding 70 percent, cash-only operations, and interstate commerce barriers that prevent efficient supply chains and national brand development. The state-legal cannabis industry generated $28.3 billion in sales during 2025 according to BDSA, with projections reaching $35 billion by 2028 assuming continued state-level legalization. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings operate in 10 to 23 states each, structured as holding companies that provide management services to state-licensed subsidiaries to minimize federal exposure.

280E Tax Burden

Section 280E creates the single largest operational cost for cannabis businesses. A dispensary with $5 million in annual revenue and $3 million in cost of goods sold faces $2 million in gross profit. With $1.5 million in operating expenses (rent, salaries, utilities, marketing), the business would show $500,000 in net income under standard accounting. Under 280E, the $1.5 million in operating expenses is not deductible, resulting in $2 million in taxable income and approximately $700,000 in federal tax liability—a 140 percent effective tax rate on actual net income. Operators respond through vertical integration to maximize cost of goods sold deductions, aggressive allocation of expenses to non-plant-touching subsidiaries, and complex entity structures. The IRS has challenged these arrangements, with Tax Court cases including Patients Mutual Assistance Collective Corp. v. Commissioner (2015) and Alterman v. Commissioner (2018) establishing narrow interpretations of allowable deductions. Rescheduling to Schedule III would eliminate 280E, reducing effective tax rates to standard corporate levels of 21 percent federal plus state taxes. The National Cannabis Industry Association estimated in 2025 that 280E relief would save the industry $1.8 billion annually, enabling price reductions, capital investment, and expansion into underserved markets.

Banking and Capital Access

Fewer than 800 financial institutions serve cannabis clients as of 2026, forcing most operators to conduct cash transactions for rent, payroll, and tax payments. Cash operations create security risks, with robberies targeting dispensaries and cultivation facilities common in California, Colorado, and Oklahoma. Operators employ armed security, armored transport, and cash management services that add 3 to 5 percent to operating costs. Lack of banking access prevents cannabis businesses from accepting credit cards, limiting customer convenience and transaction sizes. Cashless ATM systems that process debit transactions as ATM withdrawals have emerged as workarounds, though these systems face regulatory scrutiny. Some operators use payment processing services based in tribal jurisdictions or foreign banks, accepting higher fees and compliance risks. Capital markets remain closed to plant-touching cannabis businesses. U.S. stock exchanges including NASDAQ and NYSE prohibit listings of companies violating federal law. Canadian exchanges including the Toronto Stock Exchange and Canadian Securities Exchange list U.S. cannabis operators, but these listings trade over-the-counter in the United States with limited liquidity. Private equity and venture capital provide growth funding at rates of 12 to 18 percent, compared to 4 to 7 percent for conventional businesses.

Interstate Commerce Prohibition

Federal prohibition prevents interstate cannabis commerce, forcing each state to build complete supply chains from cultivation through retail. This creates inefficiencies where states with low production costs and ideal growing climates cannot export to high-cost markets. California produces significant surplus cannabis that cannot legally cross state lines, while New York and Illinois face supply shortages and elevated wholesale prices. Wholesale cannabis prices vary dramatically by state due to supply-demand imbalances and regulatory differences. Oregon wholesale flower prices averaged $800 per pound in 2025 due to oversupply, while Illinois wholesale prices exceeded $2,500 per pound. Interstate commerce would allow price arbitrage, stabilizing markets and reducing consumer costs. Brand development suffers from interstate barriers. Multi-state operators must license intellectual property to state-specific subsidiaries and cannot ship products between states, preventing economies of scale in manufacturing and marketing. National brands in conventional industries achieve cost efficiencies through centralized production and distribution that remain impossible for cannabis.

What Experts and Stakeholders Say

Industry leaders, medical researchers, law enforcement officials, and policy advocates offer divergent perspectives on federal prohibition, with consensus emerging around the need for banking access and research barriers while disagreement persists on full legalization versus incremental reform. The American Medical Association adopted a policy position in 2019 supporting rescheduling cannabis from Schedule I to enable research, stating that the current classification "is not consistent with the available evidence." The organization stopped short of endorsing legalization, emphasizing the need for FDA-approved medications developed through clinical trials. The National Academy of Sciences, Engineering, and Medicine published a comprehensive review in 2017 concluding that substantial evidence supports cannabis efficacy for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity. The report identified research barriers created by Schedule I classification as limiting the evidence base for other potential therapeutic applications. Aaron Smith, co-founder of the National Cannabis Industry Association, stated in 2025 congressional testimony that "federal prohibition forces state-legal businesses to operate in a grey area where we pay taxes but cannot access the banking system, deduct business expenses, or engage in interstate commerce that every other legal industry takes for granted." Smith advocated for descheduling rather than rescheduling, arguing that Schedule III classification would preserve criminal penalties and fail to resolve banking access. Kevin Sabet, president of Smart Approaches to Marijuana, testified before Congress in 2024 that "commercialization has led to a public health crisis with today's high-potency THC products bearing no resemblance to the marijuana of the 1970s." Sabet cited increases in cannabis use disorder diagnoses and emergency department visits in legalized states, advocating for continued prohibition with expanded access to FDA-approved cannabis-derived medications. The Drug Policy Alliance, which advocates for drug decriminalization, published a 2025 report arguing that rescheduling to Schedule III "would be a half-measure that preserves criminalization, maintains barriers to expungement, and fails to address the harms of the war on drugs." The organization supports descheduling combined with automatic expungement of federal cannabis convictions and reinvestment of tax revenue in communities disproportionately impacted by enforcement. State-level law enforcement perspectives vary by jurisdiction. The Colorado Association of Chiefs of Police issued a 2023 statement acknowledging that legalization "has not resulted in the public safety catastrophe predicted by opponents" while noting challenges with impaired driving detection and youth access prevention. The association supported federal rescheduling to resolve banking issues that complicate tax collection and regulatory oversight.

What's Next: Decision Points and Scenarios

The DEA rescheduling process, congressional legislation prospects, and 2026-2028 state ballot initiatives will determine whether federal prohibition ends through administrative action, legislative reform, or continued state-by-state legalization that forces federal accommodation.

DEA Rescheduling Timeline

The DEA's Notice of Proposed Rulemaking published in May 2024 initiated a comment period that closed in July 2024, generating more than 43,000 public submissions. The agency scheduled administrative hearings for December 2024 with testimony from medical experts, law enforcement, industry representatives, and advocacy organizations. A final rule is expected in 2026, though the timeline depends on resolution of scientific disputes and potential legal challenges. If the DEA finalizes Schedule III rescheduling, the change would take effect 30 days after publication in the Federal Register. State-licensed operators would immediately gain access to standard business tax deductions, eliminating 280E penalties. Criminal penalties for unlicensed activity would remain under 21 U.S.C. § 841, with reduced maximum sentences compared to Schedule I. Interstate commerce would remain prohibited, and banking access would not automatically improve without separate legislative action. Opponents of rescheduling could challenge the final rule in federal court, arguing that the DEA failed to follow the Administrative Procedure Act or that the scientific evidence does not support Schedule III classification. Such litigation could delay implementation by 12 to 24 months.

Congressional Legislation Prospects

The Cannabis Administration and Opportunity Act introduced by Senate Majority Leader Chuck Schumer in 2022 and reintroduced in 2024 would deschedule cannabis, establish federal taxation at rates up to 25 percent, and create grant programs for social equity and research. The legislation has not advanced to a floor vote, facing opposition from Republicans concerned about federal overreach and Democrats demanding stronger social equity provisions. The SAFE Banking Act passed the House in April 2024 as a standalone bill but stalled in the Senate. Some senators support combining banking reform with criminal justice provisions including expungement and resentencing, while others prefer a narrow banking-only approach. The 2026 congressional elections could shift the legislative landscape, with cannabis reform polling favorably among voters under 50 across party lines. A bipartisan compromise could emerge around limited reforms: banking access, 280E relief through tax code amendments, and research barriers reduction without full descheduling. Such an approach would preserve prohibition while addressing the most acute operational challenges facing state-legal businesses.

State Ballot Initiatives 2026-2028

Florida voters will consider an adult-use legalization initiative in November 2026 after the 2024 measure fell short of the 60 percent threshold. Polling in early 2026 showed 64 percent support, suggesting passage is likely. Florida's market would become the largest adult-use program by population, with projections of $4 billion to $6 billion in annual sales. Pennsylvania, Ohio, and Kentucky have active campaigns to place adult-use initiatives on 2026 or 2027 ballots. Pennsylvania's legislature considered legalization bills in 2024 and 2025 without advancing them to floor votes, making a ballot initiative the likely path. Ohio's existing adult-use program launched in 2024 provides a regional model for neighboring states. Idaho and Wyoming remain unlikely to legalize through ballot initiatives due to constitutional restrictions on citizen-initiated measures for controlled substances. These states would require legislative action, which faces opposition from conservative majorities.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — Full text of the federal statute establishing drug scheduling and penalties
• DEA Notice of Proposed Rulemaking on Marijuana Rescheduling, 89 Fed. Reg. 44,597 (May 21, 2024) — Official proposal to move cannabis to Schedule III
• Department of Health and Human Services Recommendation to Reschedule Marijuana (August 2023) — Scientific review supporting Schedule III classification
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — Tax code provision prohibiting business expense deductions for Schedule I and II substances
• Gonzales v. Raich, 545 U.S. 1 (2005) — Supreme Court decision upholding federal authority to criminalize intrastate cannabis activity
• National Academies of Sciences, Engineering, and Medicine, "The Health Effects of Cannabis and Cannabinoids" (2017) — Comprehensive review of medical evidence